Table 1 Baseline characteristics and echocardiographic data

Male

83%

77%

69%

0.61

Age (years)

61

60

63

0.18

Clinical history

Angina

43%

41%

56%

<0.001

Myocardial infarction

7%

3%

12%

0.056

Percutaneous coronary intervention

1%

3%

12%

0.013

Coronary artery bypass graft

0%

0%

0%

-

In-hospital

Anterior infarction

29%

31%

46%

0.28

Thrombolysis

56%

49%

47%

0.83

Revascularization

100%

0%

29%

<0.001

- Percutaneous coronary intervention

83%

0%

24%

- Coronary artery bypass graft

17%

0%

5%

Peak creatine kinase (U/L)

1,617 ± 1,215

1,804 ± 1,321

1,784 ± 1,654

0.66

Peak creatine kinase-MB (U/L)

165 ± 130

204 ± 182

170 ± 149

0.27

Pathological Q waves (n)^†

1.70 ± 1.57

1.96 ± 1.48

2.54 ± 2.00

0.01

Persistent ST elevation >1 mm^†

20%

34%

54%

<0.001

Echocardiography

Viable segments (16 segments model) (n)

3.39 ± 1.43

3.38 ± 1.27

0.37 ± 0.49

0.95^‡

LVEDV (ml)

98.5 ± 33.2

88.4 ± 25.2

89.5 ± 33.7

0.07

LVESV (ml)

47.0 ± 25.1

41.9 ± 19.1

42.9 ± 22.5

0.32

LVEF

54.0%

53.3%

53.5%

0.93

WMI

1.54 ± 0.27

1.57 ± 0.26

1.54 ± 0.30

0.78

Follow-up

Follow-up echocardiogram (days)

226 ± 129

178 ± 127

205 ± 134

0.07

Revascularisation (days)

25 ± 66

NA

48 ± 75

0.16^§

Risk factors

Diabetes mellitus

10%

11%

8%

0.63

Hypertension

23%

26%

36%

0.11

Hypercholesterolemia

19%

14%

17%

0.91

Current cigarette smoking

46%

35%

64%

0.003

Family history of coronary artery disease

33%

26%

20%

0.25

Medications at admission

Aspirin

14%

11%

12%

0.76

Beta-blocker

11%

12%

17%

0.58

Statins

17%

5%

10%

0.02

ACE-inhibitor

10%

5%

15%

0.11

Angiotensin II antagonist

4%

6%

7%

0.33

Medications at discharge

Aspirin

95%

99%

88%

0.04

Beta-blocker

97%

93%

92%

0.35

Statins

94%

99%

92%

0.18

ACE-inhibitor

54%

58%

68%

0.25

Angiotensin II antagonist

3%

7%

8%

0.35

Clopidogrel

65%

11%

22%

<0.001

Diuretics

5%

6%

17%

0.02